A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Register Today!
Alopecia Areata – M23-716
Read More
COPD – CLI-05993AA3-06
A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose dual combination of beclomethasone dipropionate plus formoterol fumarate (CHF 1535), both administered via pMDI in subjects with…
Influenza Vaccine – V201_03
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older. Register Today!
Alopecia Areata – HZNP-DAX-201
A Phase 2A, Open Label, Proof-of-Concept Trial of Daxdilimab for the Treatment of Moderate-to-Severe Alopecia Areata Register Today!
Maternal-Infant Research on Environmental Chemicals (Mirec-Endo – Phase II)
A study to determine whether prenatal exposure to elevated levels of various environmental chemicals, as well as other in-utero factors are related to the onset and progression of puberty, child metabolic function and growth. Click here for more information. Register Today!
Clinical Research Coordinator
Caitlyn Van Zon
About Caitlyn We’ll tell you very soon!
Obesity – I8F-MC-GPIJ
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity Register Today!
Atopic Dermatitis – ACT17207
A Phase 2, randomized, double-blind, placebo controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids. Register Today!
Christine Garceau
About Christine We’ll tell you very soon!